Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial.
Wei-Jian MeiXiao-Zhong WangYun-Feng LiYue-Ming SunChun-Kang YangJun-Zhong LinZu-Guang WuRui ZhangWei WangYong LiYe-Zhong ZhuangJian LeiXiang-Bin WanYing-Kun RenYong ChengWen-Liang LiZi-Qiang WangDong-Bo XuXian-Wei MoHai-Xing JuSheng-Wei YeJing-Lin ZhaoHong ZhangYuan-Hong GaoZhi-Fan ZengWei-Wei XiaoXiao-Peng ZhangXuan ZhangE XieYi-Fei FengJing-Hua TangXiao-Jun WuGong ChenLi-Ren LiZhen-Hai LuDe-Sen WanJin-Xin BeiZhi-Zhong PanPei-Rong DingPublished in: Annals of surgery (2022)
nCT achieved similar pCR and downstaging rates with lower incidence of perioperative distant metastasis and preventive ileostomy compared with nCRT. CAPOX could be an effective alternative to neoadjuvant therapy in LARC with uninvolved MRF. Long-term follow-up is needed to confirm these results.
Keyphrases
- rectal cancer
- phase iii
- locally advanced
- neoadjuvant chemotherapy
- open label
- clinical trial
- lymph node
- phase ii
- sentinel lymph node
- double blind
- placebo controlled
- risk factors
- cardiac surgery
- patients undergoing
- acute kidney injury
- study protocol
- mesenchymal stem cells
- cell therapy
- early stage
- smoking cessation
- free survival